



*EPW*

PATENT  
DOCKET NO. JHV-028.01

in the application of:

Gallagher, M., et al.

Application No: 10/722,357

Filed: November 24, 2003

For: Target for Therapy of Cognitive  
Impairment

Art Unit: 1641

Attorney Docket: JHV-028.01

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF FIRST-CLASS MAILING**

I hereby certify that this is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on **June 9, 2005**.

*Angela Thumann*  
Angela Thumann

**CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Because this application was filed after June 30, 2003, copies of References AA and AB are not enclosed. A copy of Reference AC is enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action or a notice of allowance** under 37 C.F.R. 1.311, and
  - the requisite Statement is below, **OR**
  - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**
  - the requisite Statement is below, **AND**
  - the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

**STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no

item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

If the Examiner has any questions, or if a teleconference would advance the instant application toward allowance, the Examiner is urged to telephone the undersigned at 202-261-7356.

Respectfully Submitted,

Date: June 9, 2005

**Customer No.: 25181**

Patent Group

Foley Hoag LLP

Seaport World Trade Center West

155 Seaport Boulevard

Boston, MA 02210

617-832-1000

617-832-7000 (FAX)



---

Gillian M. Fenton

Reg. No. 36,508

Attorney for Applicant

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>JHV-028.01</b>	Application Number <b>10/722,357</b>
		Applicant <b>Gallagher, Michela et al.</b>	
		Filing Date <b>November 24, 2003</b>	Group Art Unit <b>1641</b>
<b>U.S. PATENT DOCUMENTS</b>			

JUN 10 2005  
U.S. PATENT AND TRADEMARK OFFICE  
RECEIVED  
SC108

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,808,893	Oct. 26, 2004	Rothstein et al.	435	69.1	Oct. 23, 2000
AB	US 2005/0048488 A1	Mar. 3, 2005	Rothstein et al.	435	6	Feb. 14, 2003

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

**OTHER DOCUMENTS**
*(Including Author, Title, Date, Pertinent Pages Etc.)*

	E. Beghi et al., "Merits of a New Drug Trial for ALS?", SCIENCE, Vol. 308, 29 April 2005, pages 632-633.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.